株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アルコール性肝炎:パイプライン製品の分析

Alcoholic Hepatitis - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 302501
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
アルコール性肝炎:パイプライン製品の分析 Alcoholic Hepatitis - Pipeline Review, H2 2019
出版日: 2019年11月25日 ページ情報: 英文 105 Pages
概要

アルコール性肝炎は、肝臓の炎症です。通常、長期にわたる過度のアルコール摂取が原因で生じます。症状には、食欲の変化、口渇、体重減少、皮膚・目の黄変 (黄疸) 、発熱、疲労感などが含まれます。

当レポートでは、アルコール性肝炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アルコール性肝炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アルコール性肝炎:企業で開発中の治療薬

アルコール性肝炎:大学/機関で研究中の治療薬

アルコール性肝炎:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

アルコール性肝炎:企業で開発中の製品

アルコール性肝炎:大学/機関で研究中の製品

アルコール性肝炎の治療薬開発に従事している企業

  • Alfact Innovation
  • Conatus Pharmaceuticals Inc.
  • Generon (Shanghai) Corporation Ltd.
  • Immuron Limited
  • Intercept Pharmaceuticals, Inc.
  • Promethera Biosciences S.A.
  • Verlyx Pharma Inc.
  • アルコール性肝炎:治療薬の評価
  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アルコール性肝炎:最近のパイプライン動向

アルコール性肝炎:休止中のプロジェクト

アルコール性肝炎:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Table 1: Number of Products under Development for Alcoholic Hepatitis, H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Universities/Institutes, H2 2019
  • Table 6: Number of Products by Stage and Target, H2 2019
  • Table 7: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 8: Number of Products by Stage and Route of Administration, H2 2019
  • Table 9: Number of Products by Stage and Molecule Type, H2 2019
  • Table 10: Alcoholic Hepatitis - Pipeline by Afimmune Biopharma Ltd, H2 2019
  • Table 11: Alcoholic Hepatitis - Pipeline by Cadila Healthcare Ltd, H2 2019
  • Table 12: Alcoholic Hepatitis - Pipeline by DURECT Corp, H2 2019
  • Table 13: Alcoholic Hepatitis - Pipeline by Generon (Shanghai) Corp Ltd, H2 2019
  • Table 14: Alcoholic Hepatitis - Pipeline by Gilead Sciences Inc, H2 2019
  • Table 15: Alcoholic Hepatitis - Pipeline by Immuron Ltd, H2 2019
  • Table 16: Alcoholic Hepatitis - Pipeline by Intercept Pharmaceuticals Inc, H2 2019
  • Table 17: Alcoholic Hepatitis - Pipeline by Novartis AG, H2 2019
  • Table 18: Alcoholic Hepatitis - Pipeline by Pattern Therapeutics, H2 2019
  • Table 19: Alcoholic Hepatitis - Pipeline by PharmaKing Co Ltd, H2 2019
  • Table 20: Alcoholic Hepatitis - Pipeline by Vectus Biosystems Ltd, H2 2019
  • Table 21: Alcoholic Hepatitis - Pipeline by Verlyx Pharma Inc, H2 2019
  • Table 22: Alcoholic Hepatitis - Dormant Projects, H2 2019
  • Table 23: Alcoholic Hepatitis - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Alcoholic Hepatitis, H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Top 10 Targets, H2 2019
  • Figure 4: Number of Products by Stage and Top 10 Targets, H2 2019
  • Figure 5: Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11536IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2019, provides an overview of the Alcoholic Hepatitis (Gastrointestinal) pipeline landscape.

Alcoholic hepatitis is an inflammation of the liver. It is typically caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever and fatigue. Risk factors include alcohol use, obesity and genetic factors. Treatment includes corticosteroids and liver transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcoholic Hepatitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Alcoholic Hepatitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcoholic Hepatitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Alcoholic Hepatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 9, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Alcoholic Hepatitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcoholic Hepatitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcoholic Hepatitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcoholic Hepatitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcoholic Hepatitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alcoholic Hepatitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alcoholic Hepatitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Alcoholic Hepatitis - Overview
  • Alcoholic Hepatitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Alcoholic Hepatitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Alcoholic Hepatitis - Companies Involved in Therapeutics Development
    • Afimmune Biopharma Ltd
    • Cadila Healthcare Ltd
    • DURECT Corp
    • Generon (Shanghai) Corp Ltd
    • Gilead Sciences Inc
    • Immuron Ltd
    • Intercept Pharmaceuticals Inc
    • Novartis AG
    • Pattern Therapeutics
    • PharmaKing Co Ltd
    • Vectus Biosystems Ltd
    • Verlyx Pharma Inc
  • Alcoholic Hepatitis - Drug Profiles
    • AF-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • canakinumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DUR-928 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-652 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMM-124E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotides to Inhibit miRNA-155 for Alcoholic Liver Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentamidine isethionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMKM-02GI1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PT-7314 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • saroglitazar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • selonsertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VB-4A32 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alcoholic Hepatitis - Dormant Projects
  • Alcoholic Hepatitis - Discontinued Products
  • Alcoholic Hepatitis - Product Development Milestones
    • Featured News & Press Releases
      • Nov 12, 2019: DURECT announces positive results from the phase 2a clinical trial of DUR-928 in alcoholic hepatitis patients in a late-breaking presentation at The Liver Meeting
      • Nov 06, 2019: DURECT to host key opinion leader call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results
      • Oct 21, 2019: DURECT announces DUR-928 Phase 2a Alcoholic Hepatitis study results selected for late-breaking oral presentation at The Liver Meeting 2019
      • Sep 17, 2019: DURECT announces positive data from its Phase 2a clinical trial of DUR-928 in Alcoholic Hepatitis
      • Aug 08, 2019: Immuron reports results in severe alcoholic hepatitis clinical trial
      • Jun 18, 2019: DURECT announces completion of the 90 mg severe cohort and dose escalation committee approval to commence 150 mg dosing in patients with severe alcoholic hepatitis (AH) in its ongoing DUR-928 phase 2a AH trial
      • May 07, 2019: DURECT announces preliminary data from the ongoing DUR-928 alcoholic hepatitis phase 2a trial
      • May 03, 2019: DURECT to present preliminary data from the ongoing DUR-928 alcoholic hepatitis phase 2a trial and report first quarter 2019 financial results
      • Jan 07, 2019: DURECT provides update on its lead product candidate DUR-928
      • Nov 19, 2018: DURECT announces amendment to accelerate ongoing phase 2a trial of DUR-928 in alcoholic hepatitis (AH) by allowing dosing of severe AH patients in parallel to moderate AH patients
      • Nov 13, 2018: Generon's F-652 Shows Positive Results in "An open label, cohort dose escalation study to assess the safety and efficacy in patients with Alcoholic Hepatitis"
      • Apr 25, 2018: DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis
      • Nov 23, 2015: Generon Collaborating with Mayo Clinic to Initiate a Phase Iia Study with F-652, a First-in-Class Biologic, to Treat Patients with Alcoholic Hepatitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
Back to Top